Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway

Figure 5

Antitumor effects of UBE + PEM combined treatment versus no treatment in lung cancer cells with and without SOCS1 knockdown. (a) qRT-PCR detected SOCS1 expression levels in cells with and without treatments. (b) MTT detecting cell proliferation. (c) Invasion and (d) migration of the PC-9 and A549 cells without treatment (shNC), with UBE + PEM combined treatment but no SOCS1 knockdown (UBE + PEM + shNC) and with UBE + PEM combined treatment and SOCS1 knockdown (UBE + PEM + shSOCS1). (e) Flow cytometry showing the apoptosis of the shNC cells, UBE + PEM + shNC cells, and UBE + PEM + shSOCS1 cells. (f) Flow cytometry showing cell cycle changes. (g, h) Pathway analysis via Western blot of corresponding protein expression and their histogram representation of the shNC cells, UBE + PEM + shNC cells, and UBE + PEM + shSOCS1 cells. for comparison between the treatment groups and the sham group; for comparison between the 1 mg/ml UBE group and the UBE + PEM group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)